FINANCIAL TV CAST

ALERT / SHORT SQUEEZE / UPDATE / REVS +30%
Daily Trader
Target Price Raised To $1.00

REVENUES UP 30% FOR FY YEAR 2015-2016

Pressure BioSciences Podcast And Management Comments 1St Qtr 10-Q

Pressure Biosciences Inc PBIO (OTCBB)

We feel that PBIO will easily break thru its previous Dec high of $0.49 Cents eventually hitting our new target price of $1.00 . Wall Street Reporter feels that there is a substantial short position in the stock that could eventually propel the share price significantly upwards .

Stocks Investors Are Buying

PRIVATE PLACEMENT $5 MILLION over-subscribed / Results For Year Revs Up 30%

Pressure BioSciences to Participate in SCIEX Workshop on New Innovations Towards Industrialized Proteomics at US HUPO Conference

SOUTH EASTON, Mass., March 14, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that SCIEX, a global leader in life science analytical technologies, will present and lead a precision medicine workshop on "New Innovations Towards Industrialized Proteomics" at the annual conference of the US Human Proteome Organization ("US HUPO"). US HUPO is being held from March 13-16 in Boston, MA. Representatives from SCIEX, Pressure BioSciences, Inc., and Advaita Bioinformatics will share insightful examples of how SCIEX next-generation solutions are enabling life science researchers to unlock the potential of their discoveries using industrialized omics to enable precision medicine. The workshop will showcase examples of how SCIEX's next-generation mass spectrometry-based solutions, combined with PBI's PCT platform and Advaita's iPathwayGuide, provide the ability to industrialize omics research workflows.

Life science researchers who are striving to transition from basic research to translational research will receive information about providing sample to biology solutions, as well as on accelerating and facilitating the biomarker research pipeline, from discovery and validation to translation into biologically and clinically relevant knowledge. The workshop's seminars include:

Andrew Olson, Vice-President of Business Development at Advaita Corporation. Mr. Olsen will present an overview of the iPathway Guide for Next-Gen Proteomics, a cloud-enabled bioinformatics platform.

An audio recording will be made available after the conference. Please contact SCIEX's media contact for access (Patrick Farrell, Sniper Public Relations on behalf of SCIEX, 603-420-8828).MORE

Latest News and Target Prices

SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO) Highlighting New Co-Marketing Agreement with SCIEX, a Global Leader in Life Sciences Analytical Technologies

NEW YORK, NY / ACCESSWIRE / January 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

"In our view, the strategic sales and marketing partnership with SCIEX is major achievement for PBIO with the potential to be a major catalyst for future sales. During our coverage, PBIO's growth has been restrained by not having enough capital to invest in building a large, skilled sales team with rich industry connections. While not necessarily a panacea for this risk, adding the sales and distribution muscle of a major, worldwide industry partner to PBIO's sales efforts has the potential to be highly impactful. We are hopeful that the SCIEX relationship will result in a material increase in and acceleration of PCT's penetration into the market," stated Ajay Tandon, CEO of SeeThruEquity. "Based on the results over the past year and expectations for the near future, we are maintaining our price target of $1.57 per share."

The report is available here: PBIO January 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on all of these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

Strong momentum heading into 2016E with several catalysts

After upbeat presentations by Mr. Schumacher at our November 2015 and January 2016 Microcap Forums in New York and San Francisco, we expect PBIO's momentum to continue into 2016. In 2016E, PBIO is expecting continued top line growth, and the company appears well on its way to this goal having landed a major new strategic partner in SCIEX – a global life sciences technology leader and a leading company worldwide in the large and growing mass spectrometry industry. With this partnership in hand, we believe PBIO could show rapid and aggressive top line growth in 2016 and beyond. Finally, on the corporate side of the business, the company continues to work towards an up-list of PBIO's shares to a national exchange in early 2016, such as the NASDAQ or NYSE.

New Mass Spectrometry Partner: SCIEX

Given the large size of the biological sample preparation market opportunity relative to the size of PBIO, we were encouraged to hear management announce a new strategic partnership with leading mass spectrometry company SCIEX. SCIEX is a wholly-owned subsidiary of Danaher Corporation (DHR), a $60bn global holding company and impressive partner. In the announcement, SCIEX and PBIO agreed to jointly will promote PBIO's pressure cycling technology (PCT) sample preparation systems, including PCT-HD (PCT High Definition), with SCIEX's SWATH(R) Acquisition based next-generation proteomics, TripleTOF(R) Systems, QTRAP(R) Systems, and Triple Quad Systems. Incorporating PBIO's proprietary PCT technology should enable SCIEX to provide a complete next generation solution for proteomics, increasing the reproducibility and depth of proteomic analysis. The combined solution offers improved sample preparation in research laboratories, enabling scientists to extract more proteins reproducibly from complex sample types, potentially yielding superior biological insights and discoveries from SCIEX's proteomics platform.

Nice momentum in a 2015 filled with significant accomplishments

Led by experienced life sciences CEO Richard T. Schumacher, PBIO completed a watershed year in 2015. The company generated record quarterly sales -- reaching $0.58mn in 3Q15 versus $0.32mn in 3Q14 and guidance of $0.5mn – while advancing the adoption of its patented and enabling PCT platform throughout the industry with an expanding number of installments and new customers, many of whom are key opinion leaders in the life sciences industry. Assuming the company meets our estimates for 4Q15, we expect it will have grown revenues by approximately 35% in 2015, with guidance for further growth in the year ahead. PBIO has also succeeded in surpassing its goal of raising $5mn in a private placement over the last six months, which has been used to clean up its balance sheet and allow investments in sales, marketing and operations.

PIPE exceeds $5mn goal; announces over-subscription

On January 11, 2016, PBIO announced that it had raised an additional $250,000 in new capital in the fifth closing of a financing it started in July 2015 – exceeding management's goal of raising $5mn through its Private Placement (PIPE) over the last six months. PBIO announced it is opening a $1.25mn over-subscription for the offering, raising cumulative potential proceeds to $6.25mn. PBIO's balance sheet has been a key item to watch in our coverage of the company, as management indicated at the outset of 2015 that it would seek to raise new capital in order to eliminate its variable rate (floorless) convertible notes and fund growth in its sales and marketing team. Management has followed through on this promise, announcing concurrent with a $0.7mn financing in December that it had successfully eliminated the final portion of the remaining variable rate (floorless) convertible notes. Despite PBIO never having allowed the variable rate floorless notes to convert under the terms of the loans, we view the elimination of this risky debt as a significant accomplishment – as the floorless conversion feature carried a major risk of shareholder dilution. In all, PBIO was able to pay down over $2.7mn in variable rate loans while still exceeding its lofty sales goals in the first three quarters of 2015.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream

REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.

The company's Pressure Cycling Technology (PCT) helps researchers in the life sciences industry reproducibly extract and subsequently process more proteins from complex sample types compared to other current technologies. This allows scientists using PCT to ultimately gain superior biological insights and discoveries. By cycling between ambient and ultrahigh levels of pressure at controlled temperatures, the technology gently squeezes out proteins, lipids, or other cellular components without damaging the cell’s contents prior to studying them. This cannot be said of competitive methods to PCT.

And here is some additional breakthrough news. After several years in development, the company announced an exclusive co-marketing agreement with SCIEX - Danaher Corporation's (NYSE: DHR) $1.1 billion acquisition made back in 2009 to enter the important and growing mass spectrometry industry. The agreement will promote PCT sample preparation systems with SCIEX mass spec systems as a way to better prepare samples ahead of analyzing them in order to maximize the identification of key proteins, which can potentially lead to the discovery of new and vastly important biomarkers of disease. The agreement could add significantly to the company's revenue model in 2016 and beyond.

In November, the company reported a 55.8% increase in third quarter revenue and a 13.4% decrease in its operating loss quarter over quarter, making it the most successful financial quarter in the company's history. The SCIEX agreement could provide a significant boost to these financial results by pairing its technology with some of the most popular mass spec equipment in the market rather than relying on organic growth and direct sales.

The move could spur other mass spec companies, such as Thermo Fisher Scientific Inc. (NYSE: TMO) or Waters Corporation (NYSE: WAT), to try and strike similar deals to expand their product offerings with PCT-based technologies that improve sample preparation.

Management also made great strides in cleaning up the company's fiscal situation by eliminating all (nearly $3 million worth) of its variable rate convertible notes. With the notes being a significant overhang on the company's stock for much of the past 2-3 years, the elimination of the toxic debt should make it easier for the company to access the capital that it needs, while opening the door for the share price to move higher due to the firm's improved financial condition.

The company's plan to up-list to the NASDAQ early this year could also dramatically expand the visibility of its stock. Since many institutional investors aren't permitted to invest in over-the-counter equities, a NASDAQ up-listing could open the door to significantly more liquidity and a wider investor base. These dynamics could help the stock achieve a fairer valuation more quickly and ultimately improve long-term shareholder value.

Investors in lab instrumentation stocks, such as Harvard Bioscience Inc. (NASDAQ: HBIO) or HTG Molecular Diagnostics Inc. (NASDAQ: HTGM), may want to take a closer look at Pressure BioSciences ahead of its 2016 financial results and potential up-listing to the NASDAQ. The company has made many significant moves over the past year to improve both its financial and operational businesses and looks to be on a path of solid growth.

For more information, visit the company's website at www.pressurebiosciences.com.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

DISCLAIMER